Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck reports additional data for CETP inhibitor in CHD

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL trial in patients with atherosclerotic vascular disease showing that once-daily 100 mg oral anacetrapib (MK-0859) reduced major coronary

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE